Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workersCitation formats

  • External authors:
  • Ross J. Harris
  • Heather J. Whitaker
  • Nick J. Andrews
  • Felicity Aiano
  • Zahin Amin-chowdhury
  • Jessica Flood
  • Ray Borrow
  • Ezra Linley
  • Shazaad Ahmad
  • Lorraine Stapley
  • Bassam Hallis
  • Gayatri Amirthalingam
  • Katja Höschler
  • Ben Parker
  • Timothy J.g. Brooks
  • Kevin E. Brown
  • Mary E. Ramsay
  • Shamez N. Ladhani

Standard

Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. / Harris, Ross J.; Whitaker, Heather J.; Andrews, Nick J.; Aiano, Felicity; Amin-chowdhury, Zahin; Flood, Jessica; Borrow, Ray; Linley, Ezra; Ahmad, Shazaad; Stapley, Lorraine; Hallis, Bassam; Amirthalingam, Gayatri; Höschler, Katja; Parker, Ben; Horsley, Alexander; Brooks, Timothy J.g.; Brown, Kevin E.; Ramsay, Mary E.; Ladhani, Shamez N.

In: Journal Of Infection, Vol. 82, No. 5, 01.05.2021, p. 162-169.

Research output: Contribution to journalArticlepeer-review

Harvard

Harris, RJ, Whitaker, HJ, Andrews, NJ, Aiano, F, Amin-chowdhury, Z, Flood, J, Borrow, R, Linley, E, Ahmad, S, Stapley, L, Hallis, B, Amirthalingam, G, Höschler, K, Parker, B, Horsley, A, Brooks, TJG, Brown, KE, Ramsay, ME & Ladhani, SN 2021, 'Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers', Journal Of Infection, vol. 82, no. 5, pp. 162-169. https://doi.org/10.1016/j.jinf.2021.03.015

APA

Harris, R. J., Whitaker, H. J., Andrews, N. J., Aiano, F., Amin-chowdhury, Z., Flood, J., Borrow, R., Linley, E., Ahmad, S., Stapley, L., Hallis, B., Amirthalingam, G., Höschler, K., Parker, B., Horsley, A., Brooks, T. J. G., Brown, K. E., Ramsay, M. E., & Ladhani, S. N. (2021). Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. Journal Of Infection, 82(5), 162-169. https://doi.org/10.1016/j.jinf.2021.03.015

Vancouver

Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-chowdhury Z, Flood J et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. Journal Of Infection. 2021 May 1;82(5):162-169. https://doi.org/10.1016/j.jinf.2021.03.015

Author

Harris, Ross J. ; Whitaker, Heather J. ; Andrews, Nick J. ; Aiano, Felicity ; Amin-chowdhury, Zahin ; Flood, Jessica ; Borrow, Ray ; Linley, Ezra ; Ahmad, Shazaad ; Stapley, Lorraine ; Hallis, Bassam ; Amirthalingam, Gayatri ; Höschler, Katja ; Parker, Ben ; Horsley, Alexander ; Brooks, Timothy J.g. ; Brown, Kevin E. ; Ramsay, Mary E. ; Ladhani, Shamez N. / Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. In: Journal Of Infection. 2021 ; Vol. 82, No. 5. pp. 162-169.

Bibtex

@article{831ac4e1313f47559ffac4f6af5cb0a9,
title = "Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers",
abstract = "Background Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England. Methods Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression. Findings In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12–16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50–68%) Euroimmun, 41% (30–52%) RBD, 10% (8–14%) Roche (N) < 2% Roche (S). Interpretation Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.",
author = "Harris, {Ross J.} and Whitaker, {Heather J.} and Andrews, {Nick J.} and Felicity Aiano and Zahin Amin-chowdhury and Jessica Flood and Ray Borrow and Ezra Linley and Shazaad Ahmad and Lorraine Stapley and Bassam Hallis and Gayatri Amirthalingam and Katja H{\"o}schler and Ben Parker and Alexander Horsley and Brooks, {Timothy J.g.} and Brown, {Kevin E.} and Ramsay, {Mary E.} and Ladhani, {Shamez N.}",
year = "2021",
month = may,
day = "1",
doi = "10.1016/j.jinf.2021.03.015",
language = "English",
volume = "82",
pages = "162--169",
journal = "Journal Of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Co. Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers

AU - Harris, Ross J.

AU - Whitaker, Heather J.

AU - Andrews, Nick J.

AU - Aiano, Felicity

AU - Amin-chowdhury, Zahin

AU - Flood, Jessica

AU - Borrow, Ray

AU - Linley, Ezra

AU - Ahmad, Shazaad

AU - Stapley, Lorraine

AU - Hallis, Bassam

AU - Amirthalingam, Gayatri

AU - Höschler, Katja

AU - Parker, Ben

AU - Horsley, Alexander

AU - Brooks, Timothy J.g.

AU - Brown, Kevin E.

AU - Ramsay, Mary E.

AU - Ladhani, Shamez N.

PY - 2021/5/1

Y1 - 2021/5/1

N2 - Background Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England. Methods Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression. Findings In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12–16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50–68%) Euroimmun, 41% (30–52%) RBD, 10% (8–14%) Roche (N) < 2% Roche (S). Interpretation Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.

AB - Background Antibody waning after SARS-CoV-2 infection may result in reduction in long-term immunity following natural infection and vaccination, and is therefore a major public health issue. We undertook prospective serosurveillance in a large cohort of healthy adults from the start of the epidemic in England. Methods Clinical and non-clinical healthcare workers were recruited across three English regions and tested monthly from March to November 2020 for SARS-CoV-2 spike (S) protein and nucleoprotein (N) antibodies using five different immunoassays. In positive individuals, antibody responses and long-term trends were modelled using mixed effects regression. Findings In total, 2246 individuals attended 12,247 visits and 264 were seropositive in ≥ 2 assays. Most seroconversions occurred between March and April 2020. The assays showed > 85% agreement for ever-positivity, although this changed markedly over time. Antibodies were detected earlier with Abbott (N) but declined rapidly thereafter. With the EuroImmun (S) and receptor-binding domain (RBD) assays, responses increased for 4 weeks then fell until week 12–16 before stabilising. For Roche (N), responses increased until 8 weeks, stabilised, then declined, but most remained above the positive threshold. For Roche (S), responses continued to climb over the full 24 weeks, with no sero-reversions. Predicted proportions sero-reverting after 52 weeks were 100% for Abbott, 59% (95% credible interval 50–68%) Euroimmun, 41% (30–52%) RBD, 10% (8–14%) Roche (N) < 2% Roche (S). Interpretation Trends in SARS-CoV-2 antibodies following infection are highly dependent on the assay used. Ongoing serosurveillance using multiple assays is critical for monitoring the course and long-term progression of SARS-CoV-2 antibodies.

U2 - 10.1016/j.jinf.2021.03.015

DO - 10.1016/j.jinf.2021.03.015

M3 - Article

VL - 82

SP - 162

EP - 169

JO - Journal Of Infection

JF - Journal Of Infection

SN - 0163-4453

IS - 5

ER -